Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Basit Öğe Kaydı
dc.authorid0000-0003-0829-3912
dc.authorscopusid55550057300
dc.authorscopusid50263136900
dc.authorscopusid55899219500
dc.authorscopusid9738119600
dc.authorwosidDoğan, Emine/ABE-8376-2020
dc.authorwosidDoğan, Emine/ABB-7804-2020
dc.contributor.authorDoğan, Emine
dc.contributor.authorSever, Özkan
dc.contributor.authorÇakır, Burçin Koklu
dc.contributor.authorÇelik, Erkan
dc.date.accessioned2022-05-11T14:35:47Z
dc.date.available2022-05-11T14:35:47Z
dc.date.issued2018
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalı
dc.description.abstractPurpose: The aim of this study was to evaluate the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion (BRVO). Materials and methods: Fifty-two BRVO eyes, treated with intravitreal ranibizumab injection for ME with and without SRD, were retrospectively reviewed. Patients were divided into two groups according to spectral domain optical coherence tomography (SD-OCT). The efficacy of intravitreal ranibizumab injection at first month was assessed by analyzing the change in best-corrected VA and reduction in CMT with SD-OCT. Results: There were 21 patients with SRD and 31 patients with only CME (no-SRD). CMT was significantly greater in the SRD group than in the CME group (451 +/- 62.2 mu m vs 383.5 +/- 37.2 mu m, respectively, P<0.05). After initial intravitreal ranibizumab injection, mean VA improved from 0.87 +/- 0.26 logarithm of the minimum angle of resolution (LogMAR) to 0.54 +/- 0.27 LogMAR (P<0.01) and CMT decreased from 451 +/- 62.2 mu m to 379.3 +/- 58.6 mu m (P<0.001) in the SRD group. In the no-SRD group, mean VA improved from 0.69 +/- 0.25 LogMAR to 0.44 +/- 0.25 LogMAR (P<0.001) and the CMT decreased from 383.5 +/- 37.2 mu m to 337.7 +/- 39.4 mu m (P<0.001) at the first month visit. Eyes with SRD revealed better anatomic results and greater reduction of CMT after intravitreal ranibizumab injection (P<0.01). Conclusion: VA and CMT can be improved by intravitreal ranibizumab injection in BRVO patients with and without SRD. However, more marked improvement in macular morphology was achieved in patients with SRD than those without SRD.
dc.identifier.doi10.2147/OPTH.S162019
dc.identifier.endpage1470
dc.identifier.issn1177-5483
dc.identifier.pmid30154642
dc.identifier.scopus2-s2.0-85057737472
dc.identifier.scopusqualityQ2
dc.identifier.startpage1465
dc.identifier.urihttps://doi.org/10.2147/OPTH.S162019
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8219
dc.identifier.volume12
dc.identifier.wosWOS:000441744500002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDoğan, Emine
dc.institutionauthorSever, Özkan
dc.institutionauthorÇakır, Burçin Koklu
dc.institutionauthorÇelik, Erkan
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofClinical Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectranibizumab
dc.subjectvein occlusion
dc.subjectserous detachment
dc.subjectOptical Coherence Tomography
dc.subjectUndiluted Vitreous Cytokines
dc.subjectMacular Detachment
dc.subjectSustained Benefits
dc.subject12-Month Outcomes
dc.subjectEdema
dc.subjectBevacizumab
dc.subjectPatterns
dc.titleEffect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8219.pdf
Boyut:
605.7 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu